Physician profile
Aaron D Frey
NPI 1275913378
$1,968.18
in general payments reported to CMS, 2019-2025
36 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $108 · 2021: $226 · 2022: $214 · 2023: $500 · 2024: $240 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $171.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $151.79 | 2019-2022 | |
| Novo Nordisk INC | $151.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $135.26 | 2023 | Watchman Access System |
| Pfizer INC. | $112.08 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $93.54 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $79.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $69.83 | 2019-2023 | |
| Amgen INC. | $65.41 | 2019 | |
| Lilly USA, LLC | $59.11 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.27 | 2022-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $53.51 | 2020-2024 | Trintellix |
| Sanofi Pasteur INC. | $53.40 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $52.13 | 2020-2025 | Farxiga |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $52.01 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $38.48 | 2019-2023 | Rotateq, Gardasil 9, Vaxelis |
| Astellas Pharma US INC | $31.22 | 2023-2024 | Veozah |
| Bioventus LLC | $25.86 | 2022 | |
| Neurocrine Biosciences, INC. | $25.78 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.02 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $23.06 | 2024-2025 | Voquezna |
| Cepheid | $22.99 | 2025 | Genexpert |
| Teva Pharmaceuticals USA, INC. | $22.71 | 2019 | |
| Dexcom, INC. | $21.24 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $18.75 | 2022 | |
| Allergan, INC. | $17.64 | 2020 | |
| Esperion Therapeutics, INC. | $15.91 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $15.50 | 2023 | |
| Exact Sciences Corporation | $15.15 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $14.53 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.44 | 2021 | |
| Eisai INC. | $13.87 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.54 | 2023 | Jornay Pm |
| Medtronic, INC. | $13.11 | 2022 | |
| Sumitomo Pharma America, INC. | $10.85 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.